Science Matters: Welcome To The Oncobiome
Executive Summary
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
You may also be interested in...
Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA
Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.
Science Matters: Targeting Heme Trafficking In A Variety Of Diseases
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.